Fant 10351 publikasjoner. Viser side 348 av 415:
Revidert tiltaksutredning for lokal luftkvalitet i Bergen
Tiltaksutredningen for lokal luftkvalitet i Bergen med handlings- og beredskapsplan skal bidra til at forurensningsnivået holder seg innenfor kravene i forurensningsforskriften. Tiltaksutredningen omfatter en kartlegging av luftkvaliteten i Bergen kommune ved trafikkberegninger og utslipps- og spredningsberegninger for PM10, PM2,5 og NO 2 for Dagens situasjon 2019 og Referansesituasjonen 2030 med eksisterende og eventuelle nye tiltak. Utredningen vurderer effekten som tiltakene har for å overholde krav, men ser også på muligheten for ytterligere reduksjon i henhold til anbefalingene til helsemyndighetene. Basert på resultatene fra beregningene og i samarbeid med oppdragsgiver og referansegruppen, er det foreslått en revidert handlings- og beredskapsplan som skal behandles politisk.
NILU
2022
2022
Epidemiological studies have increasingly shown that ambient air pollution is not only associated with mortality but also with the occurrence of a number of long and short-term diseases. Further, the Global Burden of Disease study clearly indicated, that e. g. particulate matter pollution is also associated with a considerable burden of disease related to morbidity effects.
In addition to the most recent EEA’s health risk assessments, this report estimates the morbidity related health burden associated with exposure to the same three key air pollutants: fine particulate matter (PM2.5), nitrogen dioxide (NO2) and ozone (O3). Years lived with disability (YLDs) or attributable hospitalisation cases are assessed for the year 2019 for numerous European countries, depending on the respective data availability. Besides, the methodological approach as well as reviews on evidence-based health outcomes, health data and concentration-response functions are provided.
For the ten considered risk-outcome pairs, the results showed the highest morbidity related burden of disease in Europe for PM2.5 associated with chronic obstructive pulmonary disease (COPD) with 51.6 YLDs per 100 000 inhabitants ≥25 years. For NO2 the highest morbidity burden resulted from diabetes mellitus (DM) with 54.6 YLDs per 100 000 inhabitants ≥35 years. For short-term O3 exposure hospital admissions due to respiratory diseases were estimated at 18 attributable cases per 100 000 inhabitants ≥65 years.
In addition to the estimates, the report contains suggestions for further sensitivity analyses. These would allow a better assessment of the effects resulting from different input data on the results.
The estimations presented in this report are the first of its kind that are carried out for a wide range of morbidity health outcomes associated with different outdoor air pollutants in Europe, using a consistent methodology and data from European health databases.
ETC/HE
2022
2022
Utslipp og spredning av Radon-220 fra Oncoinvent, Nydalen. Underlag for utslippssøknad.
NILU har studert og vurdert utslipp til luft av radon-220 fra Oncoinvent AS i Nydalen i Oslo. Studien danner underlag for utslippssøknad. Årlig omsøkt utslipp er 70 GBq. Det største bidraget til dose/eksponering kommer fra thorondøtrene, ikke fra thoron selv. Lokale spredningsberegninger med CONCX viser at ved sterk østlig vind kan røykfanen slå ned på takterrassen på bygget hvor Oncoinvent AS har sine produksjonslokaler. Beregnet årlig dose/eksponering fra utslipp fra Oncoinvent for en person som oppholder seg 520 timer årlig på terrassen er 0,7 µSv. Beregninger med FLEXPART-wrf for et 38×20 km2 modellområde viser størst aktivitetskonsentrasjon mot nordøst og mot sørvest, det vil si nedstrøms i fremherskende vindretning. Største dose beregnes ved utslippspunktet (1 nSv time-1) og ved takterrassen.
NILU
2022
Status report of air quality in Europe for year 2021, using validated and up-to-date data
This report presents summarised information on the status of air quality in Europe in 2021, based on Up-To-Date (i.e. prior to final quality control) and validated air quality monitoring data reported by the member and cooperating countries of the EEA. It aims at giving more timely and preliminary information on the status of ambient air quality in Europe in 2021 for five key air pollutants (PM10, PM2.5, O3, NO2 and SO2). The report also gives a preliminary assessment of the progress towards meeting the European air quality standards for the protection of health and the new World Health Organization air quality guidelines, and compares the air quality status in 2021 with the previous three years. The preliminary data reported for 2021 shows that more than 11% and 9% of the monitoring stations exceeded the EU standards for PM10 and O3, respectively. The WHO AQG for PM2.5, PM10, O3 and SO2 were exceeded by 94%, 66%, 92% and 4%, respectively. Exceedances of the NO2 limit value still occur in 8 reporting countries and WHO AQG still occur in 35 reporting countries.
ETC/HE
2022
The chemical pollution crisis severely threatens human and environmental health globally. To tackle this challenge the establishment of an overarching international science–policy body has recently been suggested. We strongly support this initiative based on the awareness that humanity has already likely left the safe operating space within planetary boundaries for novel entities including chemical pollution. Immediate action is essential and needs to be informed by sound scientific knowledge and data compiled and critically evaluated by an overarching science–policy interface body. Major challenges for such a body are (i) to foster global knowledge production on exposure, impacts and governance going beyond data-rich regions (e.g., Europe and North America), (ii) to cover the entirety of hazardous chemicals, mixtures and wastes, (iii) to follow a one-health perspective considering the risks posed by chemicals and waste on ecosystem and human health, and (iv) to strive for solution-oriented assessments based on systems thinking. Based on multiple evidence on urgent action on a global scale, we call scientists and practitioners to mobilize their scientific networks and to intensify science–policy interaction with national governments to support the negotiations on the establishment of an intergovernmental body based on scientific knowledge explaining the anticipated benefit for human and environmental health.
2022
2022
Lack of mutagenicity of TiO2 nanoparticles in vitro despite cellular and nuclear uptake
The potential genotoxicity of titanium dioxide (TiO2) nanoparticles (NPs) is a conflictive topic because both positive and negative findings have been reported. To add clarity, we have carried out a study with two cell lines (V79–4 and A549) to evaluate the effects of TiO2 NPs (NM-101), with a diameter ranging from 15 to 60 nm, at concentrations 1–75 μg/cm2. Using two different dispersion procedures, cell uptake was determined by Transmission Electron Microscopy (TEM). Mutagenicity was evaluated using the Hprt gene mutation test, while genotoxicity was determined with the comet assay, detecting both DNA breaks and oxidized DNA bases (with formamidopyrimidine glycosylase - Fpg). Cell internalization, as determined by TEM, shows TiO2 NM-101 in cytoplasmic vesicles, as well as close to and inside the nucleus. Such internalization did not depend on the state of agglomeration, nor the dispersion used. In spite of such internalization, no cytotoxicity was detected in V79–4 cells (relative growth activity and plating efficiency assays) or in A549 cells (AlamarBlue assay) after exposure lasting for 24 h. However, a significant decrease in the relative growth activity was detected at longer exposure times (48 and 72 h) and at the highest concentration 75 µg/cm2. When the modified enzyme-linked alkaline comet assay was performed on A549 cells, although no significant induction of DNA damage was detected, a positive concentration-effects relationship was observed (Spearman’s correlation = 0.9, p 0.0001). Furthermore, no significant increase of DNA oxidized purine bases was observed. When the frequency of Hprt gene mutants was determined in V79–4 cells, no increase was observed in the exposed cells, relative to the unexposed cultures. Our general conclusion is that, under our experimental conditions, TiO2 NM-101 exposure does not exert mutagenic effects despite the evidence of NP uptake by V79–4 cells.
2022
2022
2022
FAIRMODE Guidance Document on Modelling Quality Objectives and Benchmarking. Version 3.3.
The development of the procedure for air quality model benchmarking in the context of the Air Quality Directive 2008/50/EC (AQD) has been an on-going activity in the context of the FAIRMODE community, chaired by the JRC. A central part of the studies was the definition of proper modelling quality indicators and criteria to be fulfilled in order to allow sufficient level of quality for a given model application under the AQD. The focus initially on applications related to air quality assessment has gradually been expanded to other applications, such as forecasting and planning. The main purpose of this Guidance Document is to explain and summarise the current concepts of the modelling quality objective methodology, elaborated in various papers and documents in the FAIRMODE community, addressing model applications for air quality assessment and forecast. Other goals of the Document are linked to presentation and explanation of templates for harmonised reporting of modelling results. Giving an overview of still open issues in the implementation of the presented methodology, the document aims at triggering further research and discussions. A core set of statistical indicators is defined using pairs of measurement-modelled data. The core set is the basis for the definition of a modelling quality indicator (MQI) and additional modelling performance indicators (MPI), which take into account the measurement uncertainty. The MQI describes the discrepancy between measurements and modelling results (linked to RMSE), normalised by measurement uncertainty and a scaling factor. The modelling quality objective (MQO) requires MQI to be less than or equal to 1. With an arbitrary selection of the scaling factor of 2, the fulfilment of the MQO means that the allowed deviation between modelled and measured concentrations is twice the measurement uncertainty. Expressions for the MQI calculation based on time series and yearly data are introduced. MPI refer to aspects of correlation, bias and standard deviation, applied to both the spatial and temporal dimensions. Similarly to the MQO for the MQI, modelling performance criteria (MPC) are defined for the MPI; they are necessary, but not sufficient criteria to determine whether the MQO is fulfilled. The MQO is required to be fulfilled at 90% of the stations, a criterion which is implicitly taken into account in the derivation of the MQI. The associated modelling uncertainty is formulated, showing that in case of MQO fulfilment the modelling uncertainty must not exceed 1.75 times the measurement one (with the scaling factor fixed to 2). A reporting template is presented and explained for hourly and yearly average data. In both cases there is a diagram and a table with summary statistics. In a separate section open issues are discussed and an overview of related publications and tools is provided. Finally, a chapter on modelling quality objectives for forecast models is introduced. In Annex 1, we discuss the measurement uncertainty which is expressed in terms of concentration and its associated uncertainty. The methodology for estimating the measurement uncertainty is overviewed and the parameters for its calculation for PM, NO2 and O3 are provided. An expression for the associated modelling uncertainty is also given. This aim of this document is to support modelling groups, local, regional and national authorities in their modelling application, in the context of air quality policy.
Publications Office for the European Union
2022
2022
Acquired drug resistance and metastasis in breast cancer (BC) are coupled with epigenetic deregulation of gene expression. Epigenetic drugs, aiming to reverse these aberrant transcriptional patterns and sensitize cancer cells to other therapies, provide a new treatment strategy for drug-resistant tumors. Here we investigated the ability of DNA methyltransferase (DNMT) inhibitor decitabine (DAC) to increase the sensitivity of BC cells to anthracycline antibiotic doxorubicin (DOX). Three cell lines representing different molecular BC subtypes, JIMT-1, MDA-MB-231 and T-47D, were used to evaluate the synergy of sequential DAC + DOX treatment in vitro. The cytotoxicity, genotoxicity, apoptosis, and migration capacity were tested in 2D and 3D cultures. Moreover, genome-wide DNA methylation and transcriptomic analyses were employed to understand the differences underlying DAC responsiveness. The ability of DAC to sensitize trastuzumab-resistant HER2-positive JIMT-1 cells to DOX was examined in vivo in an orthotopic xenograft mouse model. DAC and DOX synergistic effect was identified in all tested cell lines, with JIMT-1 cells being most sensitive to DAC. Based on the whole-genome data, we assume that the aggressive behavior of JIMT-1 cells can be related to the enrichment of epithelial-to-mesenchymal transition and stemness-associated pathways in this cell line. The four-week DAC + DOX sequential administration significantly reduced the tumor growth, DNMT1 expression, and global DNA methylation in xenograft tissues. The efficacy of combination therapy was comparable to effect of pegylated liposomal DOX, used exclusively for the treatment of metastatic BC. This work demonstrates the potential of epigenetic drugs to modulate cancer cells' sensitivity to other forms of anticancer therapy.
2022
2022